Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

James J. Hsieh, David Chen, Patricia I. Wang, Mahtab Marker, Almedina Redzematovic, Ying Bei Chen, S. Duygu Selcuklu, Nils Weinhold, Nancy Bouvier, Kety H. Huberman, Umesh Bhanot, Michael S. Chevinsky, Parul Patel, Patrizia Pinciroli, Helen H. Won, Daoqi You, Agnes Viale, William Lee, A. Ari Hakimi, Michael F. BergerNicholas D. Socci, Emily H. Cheng, Jennifer Knox, Martin H. Voss, Maurizio Voi, Robert J. Motzer

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomized trial. Objective To evaluate the relationship between tumor mutations and treatment outcomes in RECORD-3, a randomized trial comparing first-line everolimus (mTOR inhibitor) followed by sunitinib (VEGF inhibitor) at progression with the opposite sequence in 471 metastatic RCC patients. Design, setting, and participants Targeted sequencing of 341 cancer genes at ∼540× coverage was performed on available tumor samples from 258 patients; 220 with clear cell histology (ccRCC). Outcome measurements and statistical analysis Associations between somatic mutations and median first-line progression free survival (PFS1L) and overall survival were determined in metastatic ccRCC using Cox proportional hazards models and log-rank tests. Results and limitations Prevalent mutations (≥ 10%) were VHL (75%), PBRM1 (46%), SETD2 (30%), BAP1 (19%), KDM5C (15%), and PTEN (12%). With first-line everolimus, PBRM1 and BAP1 mutations were associated with longer (median [95% confidence interval {CI}] 12.8 [8.1, 18.4] vs 5.5 [3.1, 8.4] mo) and shorter (median [95% CI] 4.9 [2.9, 8.1] vs 10.5 [7.3, 12.9] mo) PFS1L, respectively. With first-line sunitinib, KDM5C mutations were associated with longer PFS1L (median [95% CI] of 20.6 [12.4, 27.3] vs 8.3 [7.8, 11.0] mo). Molecular subgroups of metastatic ccRCC based on PBRM1, BAP1, and KDM5C mutations could have predictive values for patients treated with VEGF or mTOR inhibitors. Most tumor DNA was obtained from primary nephrectomy samples (94%), which could impact correlation statistics. Conclusions PBRM1, BAP1, and KDM5C mutations impact outcomes of targeted therapies in metastatic ccRCC patients. Patient summary Large-scale genomic kidney cancer studies reported novel mutations and heterogeneous features among individual tumors, which could contribute to varied clinical outcomes. We demonstrated correlations between somatic mutations and treatment outcomes in clear cell renal cell carcinoma, supporting the value of genomic classification in prospective studies.

Original languageEnglish
Pages (from-to)405-414
Number of pages10
JournalEuropean Urology
Volume71
Issue number3
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Keywords

  • BAP1
  • Everolimus
  • Genomic biomarker
  • KDM5C
  • Kidney cancer
  • PBRM1
  • SETD2
  • Sunitinib
  • Targeted therapy
  • Tumor suppressor gene

Fingerprint Dive into the research topics of 'Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Hsieh, J. J., Chen, D., Wang, P. I., Marker, M., Redzematovic, A., Chen, Y. B., Selcuklu, S. D., Weinhold, N., Bouvier, N., Huberman, K. H., Bhanot, U., Chevinsky, M. S., Patel, P., Pinciroli, P., Won, H. H., You, D., Viale, A., Lee, W., Hakimi, A. A., ... Motzer, R. J. (2017). Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology, 71(3), 405-414. https://doi.org/10.1016/j.eururo.2016.10.007